Skip to main content
. 2016 Nov 4;7(49):80820–80841. doi: 10.18632/oncotarget.13098

Figure 2. TRAIL abrogates the tumorigenic activity of TrkAIII SH-SY5Y cells in vitro.

Figure 2

(A) Representative photographs, demonstrating the abrogation of TrkAIII SH-SY5Y but not NT SH-SY5Y or pcDNA SH-SY5Y tumourigenic activity in vitro, in the presence but not absence of TRAIL (200 ng/m). (B) Histograms demonstrating the mean (±SD) percentage change in tumour numbers grown from NT SH-SY5Y, pcDNA SH-SY5Y and TrkAIII SH-SY5Y cells, in the absence (100%) or presence of TRAIL (200 ng/ml). Tumour sphere numbers were evaluated in 10 ×10 magnification fields in triplicate experiments, each performed in duplicate (* = statistical significance compared to untreated control). (C) Representative phase contrast micrographs demonstrating the appearance of tumour spheroid grown from NT SH-SY5Y, pcDNA SH-SY5Y and TrkAIII SH-SY5Y in the absence (con) or presence of TRAIL (200 ng/ml) (bar = 1 mm).